The Law and Ethics of the Pharmaceutical Industry

The Law and Ethics of the Pharmaceutical Industry

Volumn , Issue , 2006, Pages

  Dukes, Graham ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010987796     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-51868-2.X5000-4     Document Type: Book

References (557)

1. Abbott F.M. Compulsory licensing for public health needs. The trips agenda at the WTO after the Doha Declaration on Public Health 2002, Occasional Paper Nr. 9: Friends World Committee for Consultation: Quaker United Nations Office, Geneva.
2. Abbott F.M. The Doha Declaration on the TRIPS Agreement and Public Health and the Contradictory Trends in Bilateral and Regional Free Trade Agreements 2004, Occasional Paper: Quaker United Nationals Office 14 April.
3. ABPI ABPI Code of Practice for the Pharmaceutical Industry 1992, (in revision as of 2005), Association of the British Pharmaceutical Industry, London, January.
4. ABPI Clinical Trials Compensation Guidelines 1994, Association of the British Pharmaceutical Industry, London.
5. ABPI Generic Medicines 1999, Association of the British Pharmaceutical Industry, London.
6. ABPI The Cost of Medicines-Good Value for Patients 2001, Association of the British Pharmaceutical Industry, London.
7. ABPI Animal Research for Human Medicines 2001, Association of the British Pharmaceutical Industry, London.
8. ABPI Providing Developing World Medicines 2002, Association of the British Pharmaceutical Industry, London.
9. ABPI House of Lords Select Committee: The Use of Animals in Discovering Medicines 2002, Association of the British Pharmaceutical Industry, London.
10. ABPI Clinical Trials and Children's Medicines 2005, Association of the British Pharmaceutical Industry, London.
11. ABPI The UK Blue Guide on the Advertising and Promotion of Medicines 2005, Association of the British Pharmaceutical Industry, London.
12. Achilladelis B., Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Res. Policy 2001, 30:535-538.
13. ACT-UP Pfizer Zap 2004, http://www.actupny.org/reports/Bangkok/pfizer-zap.html.
14. Adnan K. Taking up the Challenge: Business and the Global Compact 2000, Adnan Kasser: text distributed during the UN Millennium summ it, 6-8 September.
15. Adu-Bonna K. AIDS in Africa website 2001, Chapter 4, data published as of May 5th 2001, citing UNAIDS and WHO statistics.
16. AESGP A.E.S.G.P. (European Proprietary Association): The European Code of Standards for the Advertising of Medicines 1977, (1977 and later revisions), A.E.S.G.P., Paris.
17. Ahmad S.R. Bitter Facts about Drugs 1990, HAI Pakistan, Karachi.
18. Allbutt T.C. Greek Medicine in Rome 1921, Macmillan, London.
19. Allen F.K. Secret Formula-How Brilliant Marketing and Relentless Salesmanship made Coca-Cola the Best-known Product in the World 1994, Harper Business, New York.
20. Alsop R.J. The 18 Immutable Laws of Corporate Reputation 2004, Kogan Page, London.
21. Amsterdam Declaration on the promotion of patients' rights in Europe. Proceedings of a consultation at Amsterdam, 28-30 March 1994 under the auspices of the WHO Regional Office for Europe 1994.
22. Amsterdam Amsterdam statement on access to medicines 1999, (issued by a meeting organized by HAI, MSF and CPT; Amsterdam 25-26 November, 1999). Text cited in WHO Drug Information (1999): 23, 223, World Health Organization, Geneva.
23. Andrew M., Joldal B., Tomson G. Norway's National Drug Policy. Dev. Dialogue 1995, 1:25-53.
24. Angell M. The pharmaceutical industry-to whom is it accountable?. N. Engl. J. Med. 2000, 342(25):1902-1904.
25. Angell M. The Truth About the Drug Companies; How they Deceive us and What to do about it 2004, Random House, New York, NY.
26. Angell M. The Truth About the Drug Companies 2004, New York Review of Books.
27. Annan K. UN General Assembly. Follow-up to the outcome of the Millennium Summit. Report of the Secretary-General. UND. No. A/56/326 2001, UNGA, New York.
28. Anon Aleotti on "death" of Italian industry. Scrip 1984, 905:1.
29. Anon Post-coital contraceptive removed from Danish market. Outlook 1989, June 10.
30. Anon Ketoprofen switched to Rx in Italy. Scrip 1995, 21.
31. Anon Litigation Discussion Forum: Hidden Toll of DES, a Generation Later 2003, Posted 24 June 2003. Lawtomation.net, Lawrence E. Feldman and Associates.
32. APG American Pharmaceutical Group Welcomes Framework for Industry Action on Access to Medicine. London 2005.
33. APMA Australian Pharmaceutical Manufacturers Association. Code of Conduct of the Australian Pharmaceutical Manufacturers Association 2000, Australian Pharmaceutical Manufacturers Association Inc, Sydney. 13th Edition.
34. Appelbe G.E., Wingfield J. Dale and Appelbe's Pharmacy Law and Ethics 1993, The Pharmaceutical Press, London. Fifth Edition.
35. Archibugi D., Held D., Koehler M. Re-imagining Political Community: Studies in Cosmopolitan Democracy 1998, Stanford University Press, Stanford, CA.
36. Arnold J.D. Incidence of injury during clinical pharmacology research and indemnification of injured research subjects at the Quincy Research Center. Report to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research 1980, (unpublished stencil).
37. Aronson J.K. Positive inotropic drugs and drug used in dysrrhythmias. Meyler's Side Effects of Drugs 1996, 445. Elsevier, Amsterdam, Lausanne and New York at. Thirte enth Edition. M.N.G. Dukes (Ed.).
38. Arras J., Rhoden N. Ethical Issues in Modern Medicine 1989, Mayfield Publishing, Mountain View.
39. Art. 355 (d): Food Drug and Cosmetic Act, 21 U.S. Congress, Art.355(d).
40. Attaran A. Malaria drug treatment: prescriptions for curing policy 2003, Paper presented to the UN Millennium Task Force, on Access to Medicines.
41. Attaran A., Sachs J. Defining and redefining international donor support for combating the AIDS pandemic. Lancet 2001, 357:57-61.
42. Australia House of Representatives Standing Committee on Community Affairs. Prescribed Health (Part 1): Regulation and the Pharmaceutical Industry 1992, 19-20. Parliament of the Commonwealth of Australia, Canberra at.
43. Autier P., Govindaraj R., Gray R., Lakshminarayaman R., Nassery H.G., Schmets G. World Bank Study: Drug Donations in Post-Emergency Situations 2002, World Bank, Washington, DC.
44. Avorn J. Powerful Medicines 2004, Knopf, New York.
45. Balant L.P., Bechtel P. Inter-ethnic differences in dose-response studies. The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines 1994, Kluwer Academic Publishers, Dordrecht, Boston and London. S. Walker (Ed.).
46. Bale H. The Pharmaceutical Industry and Corporate Social Responsibility 2005, http://www.responsiblepractice.com/enlish/insight/ifpma.
47. Ballance R., Pogany J., Forstner H. The World's Pharmaceutical Industries 1992, Published for UNIDO, Edward Elgar Publishing, Aldershot.
48. Bannenberg W. Action on essential drugs. Presentation on behalf of WHO South Africa Drug Action Programme to the 13thth International AIDS Conference 2000.
49. Banta H.D. Worldwide interest in global access to drugs. JAMA 2001, 285:2844.
50. Barrett A. More bitter pills for big pharma. Busines Week Online 2005, 10th January.
51. Biscarini L. Anti-inflammatory analgesics and drugs used in gout. Meyler's Side Effects of Drugs 1992, 195. Elsevier, Amsterdam, London, New York and Tokyo at. 12th Edition. M.N.G. Dukes (Ed.).
52. Black D. The Behaviour of Law 1976, Academic Press, Orlando, San Diego and New York.
53. BMA Secret Remedies (1908) and More Secret Remedies (1912) 1908, British Medical Association, London.
54. BNF British National Formulary Nr. 42, September 2001 2001, British Medical Association and Royal Pharmaceutical Society, London.
55. Bok D. Universities in the Marketplace: The Commercialization of Higher Education Commercialization of Higher Education 2003, Princeton University Press, Princeton, NJ.
56. Boseley S. Drug giant ignored Vioxx heart risk. The Guardian 2004, 5th November.
57. Botros S. Ethics in medical research: uncovering the conflicting approaches. Manual for Research Ethics Committees 1992, King's College, London. C. Foster (Ed.).
58. Bowie N. Business Ethics 1982, Prentice-Hall, Englewood Cliffs, NJ.
59. Boyer N. U.S. State Department 1986, 92. as quoted by Chetley (1990) (q.v.) at.
60. Bradford H.A. Controlled Clinical Trials 1960, Blackwell, Oxford.
61. Brahams D. Safety in overdose and drug licensing. The Lancet 1990, 335:343-344.
62. Braithwaite J. Corporate Crime in the Pharmaceutical Industry 1984, Routledge and Kegan Paul, London, Boston and Henley.
63. Breggin P.R. Talking Back to Ritalin 1998, Common Courage Press, Monre, ME.
64. Breggin P.R. Ritalin Class Action Suits 2001, http://www.breggin.com/congress.html.
65. Breggin P.R. Talking Back to Ritalin 2001, Perseus Publishing, Cambridge, MA. Second Edition.
66. Broder S., Bolognesi Dm Yarchoan R., Weinhold K., Mitsura H. Credit government scientists with developing anti-AIDS drug. New York Times 1989, 28. September.
67. Bryan J. Morning sickness drugs-good news?. Jeneral Practitioner 1980, 11.
68. Buitendijk S. DES-The time bomb drug. Report of the 13th European Symposium on Clinical Pharmacological Evaluation in Drug Control 1984, World Health Organization, Regional Office for Europe, Copenhagen.
69. Buse K., Walt G. Global public-private partnerships for health, parts I and II. Bull. World Health Org. 2000, 78:549-561.
70. Buse K., Walt G. Global public-private partnerships for health, parts I and II. Bull. World Health Org. 2000, 78:699-709.
71. BVG Besluit Verpakte Geneesmiddelen (Netherlands Decree on Packaged Medicines) 1963.
72. Byström M., Einarsson P. TRIPS: Consequences for Developing Countries: Implications for Swedish Development Cooperation 2001, SIDA, Stockholm.
73. Cambanis T. Cancer drug pitched in support groups-effort highlights an ethical debate. Boston Globe 2002, A1. 12 November 2002.
74. Canada Drugs Directorate. Canadian Foundation and Drugs Programme: Roles and Consultation Related to Advertising Review and Complaint Adjudication 1997, Policy Issues, February 18, 1997.
75. Cargill D. Self-treatment as an alternative to rationing medical care. Lancet 1967, 1:1377-1378.
76. Carter Investigation by the Carter Foundation into the manufacturing costs of generic companies. Data cited at SEAM 2003 (q.v.) 2003.
77. CC (1101): Civil Code of France. Art. 1101.
78. CDC National Center for HIV, STD and TB Prevention 2001, figures available on the Centre's website as of May 5th 2001.
79. CDER 2001 Report to the Nation: Improving Public Health Through Human Drugs 2001, Centre for Drug Evaluation and Research (CDER), Rockville MD.
80. CDER CDER Report to the Nation: 2000 2005, http://www.fda.gov/cder/reports/RTN2000/RTN2000-3.HTM.
81. CEO Campaign for a Corporate-Free U.N. 2000, Corporate European Observatory, Amsterdam.
82. CERES Jay P. Medicolegal investigations. Ceres News 2005, 27. Consulted: 4 April 2005.
83. Cervello V. Recherches cliniques et physiologiques sur la paraldéhyde. Arch. Ital. Biol. 1884, 6:113-134.
84. Encyclopaedia of Applied Ethics 1998, Academic Press, San Diego, London, Boston. R. Chadwick (Ed.).
85. Chernavsky A Homepage: The Pharmaceutical Industry 2005, Consulted 16 May.
86. Chetley A. A Healthy Business? World Health and the Pharmaceutical Industry 1990, Zed Books, London.
87. Childress Compensating injured research subjects: The moral argument. Hastings Centre Report 1976, 6:21-27.
88. China China Gets Tough on Counterfeit Medicine Makers 2000, Applesforhealth.com, 2(Nr 28), December 8th 2000.
89. CIA National Intelligence Estimate: The Global Infectious Disease Threat and its Implications for the United States 2000, Central Intelligence Agency, Washington, DC.
90. CIOMS Guidelines for Biomedical Research involving Human Subjects 1982, Council for International Organizations of Medical Sciences, Geneva.
91. CIPR Report of the UK Commission on Intellectual Property Rights, September 2002 2002, Her Majesty's Stationery Office, London.
92. Class S. Whither generics? Why major restructuring lies ahead. J. Gener. Med. 2005, 2(3):232-239.
93. CMH Commission on Macroeconomics and Health, 2001 2001.
94. CNN Documents: Prozac use reports more likely to list suicide. CNN News 2005, January 4th 2004, posted 1906 GMT.
95. Cockburn R., Newton P.N., Kyeremateng A., Akunyili D., White N.J. The global threat of counterfeit drugs. PloS Medicine (Public Library of Science) 2005, 2(4):e100.
96. COE Abuse of Medicaments: Report by a Working Party, 1972-1973 1975, Council of Europe, Strasbourg.
97. Collier J. Regulating the regulators. Lancet 2002, 360(9427):2199.
98. Collier J., Iheanacho I. The pharmaceutical industry as an informant. Lancet 2002, 360(9343):1405-1409.
99. Companies Act United Kingdom: Companies Act 1985, HMSO, London.
100. Congress U.S. Congress: (1906) An Act for preventing the manufacture, sale or transportation of adulterated or misbranded or poisonous or deleterious foods, drugs, medicines and liquors. 59th Congress, 1st Session, 34 US Statutes 768 1906.
101. Copeman W.S.C. The Worshipful Society of Apothecaries of London: A History 1617-1967 1967, Pergamon Press, Oxford.
102. Correa C. Implication of the Doha Declaration on the TRIPS Agreement and Public Health. Health Economics and Drugs: EDM Series Nr. 12 2002, World Health Organization, Geneva.
103. Correa C. Protection of Data Submitted for the Registration of Pharmaceuticals. South Centre 2002.
104. CPA Prescription medicines code of practice authority. Monthly Reports issued by the Association of the British Pharmaceutical Industry, 1993-2005 (continuing) 2005.
105. CPBC Code of Ethics. College of Pharmacists of British Columbia 2005, Consulted 3 February 2005. http://www.bcpharmacists.org/standards/ethicslong.
106. CRA Innovation in the Pharmaceutical Sector: A Study Undertaken for the European Commission 2004, Charles River Associates, London.
107. CS Colloidal Silver, CS Pro and the FDA 2004, Consulted 23.04.2005. http://www.csprosystems.com/CSInfoPg.html.
108. CS Colloidal Silver Home Page 2005, Consulted 18 April. http://educate.yourself.org/cs/.
109. CSTS Special Focus: Genome Patents. Center for the Study of Technology and Society 2005, http://www.tecsoc.org/biotech/focuspatents.htm.
110. Daemmerich A. Regulatory laws and political culture in the United States and Germany. Regulation of the Pharmaceutical Industry 2003, 11-41. Palgrave/Macmillan, London at. J. Abraham, S.H. Lawton (Eds.).
111. DAP Action programme on essential drugs. Report of the Expert Committee on National Drug Policies. (WHO/DAP/95.9) 1995, World Health Organization, Geneva.
112. DAP Drug Action Programme: Guidelines for Drug Donations. DAP 96/2 1996, World Health Organization, Geneva.
113. Datamonitor Impact of patent expiry on the top five pharmaceutical companies. J. Gener: Med. 2004, 1(4):381-384.
114. Davidoff F., DeAngelis C.D., Drazen J.M., Hoey J., Høygaard L., Horton R., Kotzin S., Nicholls G., Nylenna M., Overbeke J.P.M., Sox H.C., Van der Weyden M.B., Wilkes M.S. Sponsorship, Authorship and Accountability. Lancet 2001, 358:854-856. (Also published in other medical journals).
115. De Stasio S., McClay N. Review of the European pharmaceutical legislation. J. Gener. Med. 2004, 1(4):295-304.
116. De Vries T.P.G.M., Henning R.H., Hogerzeil H.V., Fresle D.A. Guide to Good Prescribing (1993). WHO/DAP/93.1 1994, WHO, Geneva.
117. Deangelis C.D., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R., Kotzin S., Laine C., Marusic A., Overbeke J.P.M., Schroeder T.V., Sox H.C., Van der Weyden M.B. Is this clinical trial fully registered?. JAMA 2005, (Early Release, posted May 23rd, 2005).
118. Defoe D. A Journal of the Plague Year. London 1722.
119. DFID Access to Medicines: DFID Policy Division Plans 2003/2004 2003, DFID, London.
120. DFID Increasing Access to Essential Medicines in the Developing World: UK Government Policy and Plans 2004, DFID, London.
121. DFID Increasing Access to Essential Medicines in the Developing World 2005, DFID, London.
122. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of Innovation in the Pharmaceutical Industry. J. Health Econom. 1991, 10:107-142.
123. DMFA Danish Ministry of Foreign Affairs. Review and Appraisal Report 1995, Euro Health Group A/S and Uganda Essential Drugs Programme, Essential Drugs Management Programme, Uganda.
124. Doesgenomes Human Genome Project Information: The Human Genome Program of the U.S. 2005, Department of Energy Office of Science. http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml.
125. Dollery C.T. Mercurial diuretics. Side Effects of Drugs 1972, Vol. VII. Excerpta Medica, Amsterdam. L. Meyler, A. Herxheimer (Eds.).
126. Douglas J.D. Liability for medical injuries caused by ADR-An industrialist's view point. Detection and Prevention of Adverse Drug Reactions 1984, Almqvist and Wiksell International, Stockholm. H. Byström, N. Ljungstedt (Eds.).
127. Drahos P., Braithwaite J. Intellectual property, corporate strategy, globalisation: TRIPs in context. Wisc. Int. Law. J. 2002, 20:451-480.
128. Drahos P. The Free Trade Agreement and the Pharmaceutical Benefits Scheme 2004, Evatt Foundation, University of Sydney.
129. Drugintel Raplon (rapacuronium). DrugIntel Website. Consulted February 2nd 2005 2001.
130. DTB Yasmin advert withdrawn-why and how. Drugs Therap. Bull. 2003, 41(3):1-2.
131. DTI Department of Trade and Industry. Guide to the Consumer Protection Act 1987 1987, London.
132. Dukes M.N.G. Patent Medicines and Autotherapy in Society 1963, Drukkerij Pasmans, The Hague.
133. Dukes M.N.G. The paradox of clioquinol and SMON. Iatrogenic Diseases 1981, Oxford University Press, Oxford, New York and Toronto. Second Edition, Update. P.F. D'Arcy, J.P. Griffin (Eds.).
134. Dukes M.N.G. The epidemiology of adverse reactions. Detection and Prevention of Adverse Drug Reactions 1984, Almqvist and Wiksell International, Stockholm. H. Byström, N. Ljungstedt (Eds.).
135. Dukes M.N.G. The Effects of Drug Regulation: A Survey Based on the European Studies of Drug Regulation. For the World Health Organization's Regional Office for Europe 1985, MTP Press, Boston.
136. Dukes M.N.G. The true history of vaccination. Paper presented at the World Health Organization's Regional Office for Europe 1987.
137. Dukes M.N.G. Report to the World Bank on the Drugs Inspectorate in Uttar Pradesh 2001.
138. Dukes M.N.G. Accountability of the pharmaceutical industry. Lancet 2002, 360:1682-1684.
139. Dukes M.N.G. Hormone replacement therapy (2004). Side Effects of Drugs Annual 27 2004, 423-426. Elsevier Science Publishers, Amsterdam, Boston etc. at. J.K. Aronsen (Ed.).
140. Dukes M.N.G., Lunde I. The regulatory control of non-steroidal anti-inflammatory agents. Eur. J. Clin. Pharmacol. 1981, 19:3-10.
141. Dukes M.N.G., Vernengo M., Watt R.L. Pharmaceutical regulation and legislation. Managing Drug Supply 1997, Management Sciences for Health, Boston, MA. Second Edition. J. Quick (Ed.).
142. Dukes G., Mildred M., Swartz B. Responsibility for Drug-Induced Injury 1998, IOS Press, Amsterdam, Berlin and Oxford. Second Edition.
143. Dunne J.F. (1993): Personal communication.
144. Dworkin R Taking Rights Seriously 1977, Gerard Duckworth, London.
145. Dye C., Williams B., et al. Erasing the world's slow stain: Strategies to beat multidrugresistant tuberculosis. Science 2002 295:2042-2046. http://www.tballiance.org/2_1_2_MDR_TB.asp.
146. Dyer C. Halcion banned in U.K. Br. Med. J. 1991, 303:877.
147. Dyer C. New 20 year patents threaten to end AIDS drugs for developing countries. Brit. Med. J. 2004, 329:1308.
148. EC EC Commission: Tiered Pricing for Medicines exported to Developing Countries, measures to prevent their reimportations, and tariffs in developing countries. EC Brussels 2002.
149. EC EC Commission Directive 2003/94/EC of 8 October 2003, laying down the principles and guidelines for good manufacturing practice in respect of medicinal products for human use and investigational medicinal products 2003.
150. EC Commission of the European Communities: Proposal for a Regulation of the European Parliament and of the Council on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems. Brussels 2005.
151. EC E.C.: Council Directive 84/450/EEC of 10 September 1984 relating to the approximation of the laws, regulations and administrative provisions of the Member States concerning misleading advertising 1984, 1984/450, Commission of the European Communities, Brussels.
152. EC European Community. Directive on liability for defective products. (85) 374 1985, 1985/374, Commission of the European Communities, Brussels.
153. EC Council Regulation (EEC) Nr. 2377/90 of 26 June 1990 laying down a Community Procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin 1990, 1990/2377.
154. EC Council Directive Nr. 92/27/EEC of 1992 on the packaging of medicinal products for human use 1992, 1992/27.
155. EC Council Directive 92/28/EEC of 31 March 1992 on the advertising of medicinal products for human use. Off. J. Eur. Commun. L 113(13-18), Art 4(1) 1992, 1992/28.
156. EC Council Directive 96/22/EC of 29 April 1996 concerning the prohibition on the use in stockfarming of certain substances having a hormonal or thyrostatic action and of beta-agonists, and repealing Directives 81/602EEC, 88/146/EEC and 88/299/EERC 1996, 1996/22.
157. EC Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products 2001, 2001/82.
158. ECC EC Commission, Compulsory Licensing and Data Protection 2001.
159. ECJ Marketing Authorisation for Generics: Judgment of the European Court of Justice, December 9th 2004 (C-367/03) 2003, 36/03.
160. Editorial BMJ editorial: Regulating the pharmaceutical industry. Br. Med. J. 1997, 315:200-201.
161. EDM Data provided by WHO/EDM staff, March 2001 2001.
162. E-drug website: ARV parallel export from Africa to Europe. Report from W. Bannenberg, 7 October 2002, E-drug-digest.
163. Regulation of Vioxx: Success or Failure? (Summary of a discussion between experts). Uppsala Reports, April, 11-13 2005, I.R. Edwards (Ed.).
164. Edwards N. Molecule of the Month - Taxol 2003, (Accessed 21 November 2002). http://www.bris.ac.uk./Depts/Chemistry/MOTM/taxol.htm.
165. EGA European Generic Association: Statements on line 2003, October 2003; also statements to the EGA Annual Conferenc, Rome, 10-11 November. European Generics Association, Brussels. http://www.egagenerics.com.
166. Ehrlich P., Hata S. Die Experimentelle Chemotherapie der Spirillosen (Syphilis, Rückfallfeber, Hühnersprillose, Frambösie) 1910, J Springer, Berlin.
167. EIGP Code of Practice for Qualified Persons 2005, 2005, EIGP, Sweden.
168. Elliott C. Pharma Buys a Conscience. The American Prospect 2001, 12(17). 24 September 2001.
169. Elliot C. How the Drug Industry is Branding itself with Bioethics 2004, Medical Examiner website; posted December 15th 2003; consulted 15th February.
170. Enstad M. Comparison of Drug approval Norway - The Netherlands: 1985-1994 1995, Department of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht.
171. Ernst E. Risks associated with complementary therapies. Meyler's Side Effects of Drugs 2000, Elsevier, Amsterdam, Lausanne, New York and Oxford. Fourteenth Edition. M.N.G. Dukes, J.K. Aronson (Eds.).
172. ESC Economic and Social Council: Substantive issues arising in the application of the International Convenant on Economic. Social and Cultural Rights. General Comment Nr. 14 (2000), The right to the highest attainable standard of health. 11 August 2000 2000.
173. ESN Ethics Corner - "point". Endocrine Soc. News 2002, 27(1):1-5. 2002: Anon.
174. EUDRA EU: Rules Governing Medicinal Products in the European Union 2004, Vol. 9. June 2004, Pharmacovigilance. European Commission.
175. European Commission Scientific Conference on Growth Promoters and Meat Production - Proceedings 1996, Office for Official Publications of the EU Communities, Luxemburg.
176. Everard M. The AIDS medicines and diagnostics facility. Presentation to the SEAM/Rockefeller Symposium 2003.
177. FDA Environmental inspection report dated December 9th 1991 and March 3-4, for Upjohn Co., Kalamazoo, Mich. (authors: Erspamer D.M. and Young R.S.K.) 1992, Food and Drug Administration, Rockville, MD.
178. FDA FDA Consumer Education: Counterfeit Medicines - Filled with Empty Promises 2004, September 17th 2004, U.S. Food and Drug Administration.
179. FDA/VET http://www.fda.gov/ora/inspect_ref/iom/ChapterText/580.htm.
180. Felleskatalog over Farmacoytiske Spesialpreparater markedsfort I Norge (Joint Compendium of Pharmaceutical Specialities marketed in Norway) 1999, Felleskatalog, Felleskatalogen A.S., Oslo.
181. Filehne W. Über das Pyramidon, ein antipyrinedrivat. Berl. Klin. Wschr. 1884, 7:641-642.
182. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 1929, 10:226-236.
183. FMF Feminist Majority Foundation (FMF): FDA considers restrictions on Mifepristone. Fem. Maj. 2000, 12:1.
184. Folb P.I., Dukes M.N.G. Drug Safety in Pregnancy 1990, Elsevier, Amsterdam, New York and Oxford.
185. Fontanarosa P.B., Rennie D., DeAngelis C.D. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA 2004, 292(21):2647-2650.
186. Foster C. What are ethics, and can they be regulated?. Regulation of the Pharmaceutical Industry 2003, Palgrave Macmillan, London. J. Abraham, S.H. Lawton (Eds.).
187. Frost R. Corporate Social Responsibility and Globilization: A Reassessent 2005, http://www.aworldconnected.org/article.php/524.html.
188. Gandhi I. Address to WHO Geneva 1981, cited by Xavier N.V. (q.v.), May 1981.
189. GAO General Accounting Office: NIH clinical trials: various factors affect patient participation. Report to Congressional Requesters. September 1999.
190. Garratt C. Data presented to the MSF Working Group on Intellectual Property Rights. Paris, 4-5 April 2005 2005, (unpublished).
191. Ghana Increasing Access to Medicines: An Assessment and Policy Options for Ghana 2003, Ministry of Health, Accra, Ghana, and DFID Health Systems Resource Centre, London.
192. Giles H.Mc. Encephalopathy and the fatty degeneration of the liver. Lancet 1965, I:1075.
193. Gillespie-White L. What did Doha Accomplish? 2001, International Intellectual Property Institute, November 19th, 2001.
194. GNN Guerilla News Network: Fighting Big Pharma in Little Digwall 2005, http://gnn.tv/articles.
195. Goldstein R. Drug Industry Scandal a "Crisis" 2004, Global Policy Forum, New York.
196. The Pharmacological Basis of Therapeutics 1941, Macmillan, New York. L.S. Goodman, A. Gilman (Eds.).
197. Goozner M. The $800 million Pill; the Truth Behind the Cost of New Drugs 2004, University of California Press, Berkeley and Los Angeles, California.
198. Gorlin J. An Analysis of the Pharmaceutical-Related Provisions of the WTO TRIPs (Intellectual Property) Agreement 1999, IP Institute.
199. Gorlin J. Encouragement of New Clinical Drug Development: The Role of Data Exclusivity 2000, IFPMA, Geneva.
200. Greider K. The Big Fix: How the Pharmaceutical Industry Rips off American Consumers 2003, Perseus Books, Cambridge, MA.
201. Griffin J.P. The seven deadly sins: a U.K. view. Quality control in Toxicology 1977, 29. MTP Press, Lancaster. G.E. Paget (Ed.).
202. Griffin J.P. The seven deadly sins: a U.K. view. Quality Control in Toxicology 1977, 31. MTP Press, Lancaster. G.E. Paget (Ed.).
203. GSK The Glaxo Smith Kline Code of Conduct 2001 2001, Quoted from Society and Environmental Review, GSK, London.
204. GSK Clinical Trials in the Developing World 2002, Glaxo SmithKline, London.
205. GSK Developing World Challenges: Access to Health Care - GSK's Approach 2004, GSK.
206. Guilloux A., Moon S. Hidden Price Tags: Disease-Specific Drug Donations: Costs and Alternatives 2000, Médécins sans Frontières, Geneva.
207. GUSTO An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N. Engl. J. Med. 1993, 329(10):673-682.
208. 't Hoen E. TRIPS, pharmaceutical patents and access to essential medicines: A long way from Seattle to Doha. Chic. J. Int. Law 2002, 3(1):27-46.
209. HAI Health Action International. Drug policy at the 49th World Health Assembly. [Briefing paper] 1996.
210. HAI Attending to a Sick Industry 2004, Health Action International, Amsterdam.
211. H.P. "Stalinon": A therapeutic disaster. B.M.J. 1958, 515. see also Sem. Thérap., 34(I).
212. H.P. Stalinon: A therapeutic disaster. B.M.J. March 1st 1958, 515.
213. Harvey K. The Pharmaceutical Benefits Scheme: History, Current Status and Post-Election Prognosis 2001, http://www.econ.usyd.edu.au/drawingboard/digest/0111/harvey.html.
214. Hawthorn F. The Merck Druggernaut: The Inside Story of a Pharmaceutical Giant 2003, Wiley, Hoboken, NJ.
215. Healy D. Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression 2004, New York University Press, NY.
216. Healy S. Am Bisome price reduction benefits patients. MSF Access News, July 2004, 1 2004.
217. Held D. (1998): Democracy and globalisation. In: Archibugi D. (Ed.): (q.v.) at pp. 11-27.
218. Henderson D. The role of business in the modern world (Institute of Economic Affairs). Ciited by Brittan S. The not so obvious corporate task. Financial Times, 27 August 2004.
219. Henry D., Lexchin D. The pharmaceutical industry as a medicines provider. Lancet 2002, 360:1590-1595. (16 November).
220. Henry D., Lexchin D. The pharmaceutical industry as a medicines provider. Lancet 2002, 360(9345):1590-1595.
221. Herxheimer A. Relationships between the pharmaceutical industry and patients' organizations. Br. Med. J. 2003, 326:1208-1210.
222. HGA HGA: The Human Genome Gold Rush 2000, Human Genetics Alert, press briefing.
223. HOC House of Commons: Select Committee on Health (Fourth Report). London, April 2005.
224. Hofmann-LaRoche Advertisement: "The Sixties" 1970, quoted by Medawar C., Power and Dependence, Social Audit, London 1991.
225. Hogerzeil H. V. (undated): Evidence presented to the Working Group on Access to Drugs. United Nations Millennium Project, 2003-5.
226. Hogerzeil H.V., Casanovas J. Access to Essential Medicines as part of the Fulfilment of the Right to Health 2003, (undated), Unpublished paper made available to the author, 2003.
227. Hogerzeil H.V., Bimo, Ross-Degnan D., Laing R.O., Ofori-Adjei D., Santoso B., Chowdhury A.K.A., Das A.M., Kafle K.K., Mabadeje A.F.B., Massele A.Y. Field tests for rational drug use in twelve developing countries. Lancet 1993, 342:1408.
228. Holm S. Forgetting to be Nice-The National Institute for Clinical Excellence's Preliminary Recommendations Concerning Drugs for the Treatment of Alzheimer's Disease 2005, March, Cardiff Centre for Ethics Law and Society.
229. Holmer A.F. Innovation is key mission. USA Today, May 31st 2002.
230. Home Office Data on Animal Experiments in the United Kingdom during the year 2000 2001, as cited by ABPI 2001 (q.v.).
231. Horton R. Comment: Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004, 364(9446):1995-1996.
232. HRG Health Research Group: Letter to FDA Calling for Criminal Investigation of Astra Zeneca 2004, HRG Publication Nr. 1703, August 3rd, 2004.
233. HRREC Human Rights Research and Education Centre: Interdisciplinary studies in law: globalization, justice and law 2004, 14 September 2004, University of Ottawa.
234. Hubscher O. Ethics of drug trials in developing countries. World Health Forum 1993, 14:25-27.
235. Hunt P. UN pricks pharma's conscience 2004, Address to the Novartis Foundation for Sustainable Development (NFSD), Basel NZZ Online, December 24th, 2004.
236. Huttin C. Experiences with reference pricing. Int. J. Risk Safety Med. 2002, 15(2):85-91.
237. IAPCG Interagency Pharmaceutical Coordination Group: Report on Activities in 1996-1999 2000, WHO/UNICEF/UNFPA/World Bank.
238. ICESCR International Covenant on Economic, Social and Cultural Rights 1966, Office of the High Commissioner for Human Rights, United Nations, Geneva.
239. ICESCR International Convenant on Economic, Social and Cultural Rights, adopted by the UN General Assembly, 1966 1976.
240. IFPMA International Federation of Pharmaceutical Manufacturers' Associations. Code of Pharmaceutical Marketing Practices Geneva 1994.
241. IFPMA Merck Mectizan Donation Program 2004, IFPMA, Geneva.
242. IMS 2004, http://open.imshealth.com/webshop2/IMSinclude/i_article_20040518b.asp.
243. INRUD INRUD update: in INRUD news. Newslett. Int. Network Rational Use of Drugs 2002, 11:1-2.
244. IRENE Controlling Corporate Wrongs: the Liability of Multinational Corporations. Report of a seminar held at the University of Warwick 2000.
245. Jaeger K. As cited by Meadows M: Greater Access to Generic Drugs. Statement by the Food and Drug Administration 2002.
246. James A. Medicines, society and industry. Lancet 2002, 360:1346.
247. Jarrett S. UNICEF bulk procurement of vaccines and pharmaceuticals. Presentation to the SEAM/Rockefeller Symposium 2003.
248. Jayasuriya D.C. Regulation of Pharmaceuticals in Developing Countries 1985, World Health Organization, Geneva.
249. Jennings M.M. Business: Its Legal, Ethical and Global Environment 1987, South-Western College Publishing, Cincinnati, OH. Fourth Edition.
250. Jolleys J.V., Oleson F. A comparative study of prescribing hormone replacement therapy in USA and Europe. Maturitas 1996, 23:47-53.
251. Jorge M.F. TRIPS-plus provisions in trade agreements and their potential adverse effects on public health. J. Gener. Med. 2004, 1(3):199-211.
252. Joseph K. Hansard (House of Commons Debates). 847, Nr. 22 1972, 440-441. Cols.
253. Jüni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364(9446):2021-2029.
254. Kaldeway H., Wieringa N., Herxheimer A., et al. A searching look at advertisements 1994, University of Groningen and International Organization of Consumers Unions.
255. Kalish S., Gurwitz J.H., Krumholz H., et al. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J. Gen. Int. Med. 1995, 10:321-330.
256. Kanavos P. The Economic Impact of Pharmaceutical Parallel Trade 2003, study undertaken with support from Johnson and Johnson, November, London School of Economics and Political Science.
257. Kaplan W.A., Laing R.D., Waning B., Levison L. Pharmaceutical regulation and quality assurance 2002, Unpublished paper by the Boston University School of Public Health for the RPMPlus Project.
258. Kaplan W.A., Laing R.D., Waning B., Levison L. The impact of regulatory interventions on pharmaceutical access and quality: what is the evidence and where are the gaps in our knowledge? 2003, Unpublished paper by the Boston University School of Public Health, 1 February.
259. Karst K. Presages to the coming war over generic biologics. J. Gen. Med. 2004, 1(2):155-163.
260. Kast A. Sulfonal, ein neues Schlafmittel. Berl. Klin. Wschr. 1888, 25:309-314.
261. Kaul I. Global public goods: a new way to balance the world's trade. Le Monde Diplomatique 2000, June.
262. Kawasaki E., Patten J. Drug supply systems of missionary organizations: identifying factors affecting expansion and efficiency. Case Studies from Uganda and Kenya, Boston, WHO/EDM 2002.
263. Kent Chicago-Kent College of Law: Papers and Commentaries on Gene Patents 2005.
264. Kew S.T. Industry gifts and hospitality-what are the acceptable limits? Berita Akademi, 23(1), also citing Fitzpatrick C: No more free launches. BMJ 2004, 327-342. 2003.
265. Kim J., Millen J., Irwin A., Gershman J. Dying for Growth: Global Inequality and the Health of the Poor 2000 2000, Common Courage Press, Monroe, ME.
266. Kinney E.R. The international human right to health. Indiana Law Rev. 2001, 34:1465.
267. Korchagina V. Ministry forming agency to fight fake pills. Moscow Times 2001, 10th October.
268. Kreeger K.T. Some researchers are pleased, others indifferent, as RU 4876 moves towards ready availability in US. The Scientist 1994, 8(16):1.
269. Laing R., Waning B., Gray A., Ford N., t'Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet 2003, 361:1723-1729.
270. Laing R.D. Health and pharmacy systems in developing countries. Paper delivered to the WHO/WTO Workshop on Differential Pricing and Financing of Essential Drugs 2001.
271. Laing R.D., Hogerzeil H.V., Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Pol. Plan. 2001, 16:13-20.
272. Laurence D.R., Carpenter J.R. A Dictionary of Pharmacology and Allied Topics 1998, Elsevier, Amsterdam.
273. Lawton V. Evidence presented to the House of Commons Select Committee. Cited in: "We'll fix pharma's image" industry tells UK MP's. Scrip, 3021 2004, 2, January 19th, 2005.
274. Poverty, Inequality, and Health: An International Perspective 2001, Oxford University Press, New York. D.A. Leon, G. Walt (Eds.).
275. Lesney M.S. Pharmaceutical industry issues its plan for voluntary clinical trials registry. OB/GYN News 2005, February 1st.
276. The Future of Medicines in Health Care: Scenario Report for the Netherlands Group on Future Scenarios for Health Care 1994, Bohn Stafleu van Loghem, Houten, The Netherlands. H.G.M. Leufkens (Ed.).
277. Levi M., Shapiro S. Metamizol; een honderjarige treurnis. (Metamizol: a century of misery). Ned. Tijdschr. Geneesk 1987, 131:1680.
278. Lewis T. Clinical science. Br. Med. J. 1933, ii:717.
279. Lexchin J. What information to physicians receive from pharmaceutical representatives?. Can. Fam. Phys. 1997, 43:941-945.
280. Lexchin J., Bero L.A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br. Med. J. 2003, 326:1167-1170.
281. Light D.W., Lexchin J. Will lower drug prices jeopardize drug research?. Am. J. Bioeth. 2004, 4(1):W3-W6.
282. Lilly Building Healthier Societies Through Partnership-May 2004 Update 2003, http://www.lillyMDR-TB.com.
283. Lohmann L. Whose common future?. The Ecologist 1990, 20(3):82-83.
284. López R. (1997): Personal communication to Barbara Mintzes (see Mintzes B).
285. Los A.B.M., Smit Sibinga C.T. De persoonlijke verantwoordelijkheid van de bloeddonor voor de veiligheid van de bloedtransfusiepraktijk. Ned. Tijdschr. Geneesk. 1989, 133:1157-1158. (The personal responsibility of the blood donor for the safety of transfusion practice).
286. Loucks M. Statements cited by Angell M. (op. cit 2004) 2003, 232-233.
287. Love J. Frequently asked questions about compulsory licensing. Int. J. Risk Safety Med. 2000, 13:2.
288. Lunde P.K.M. WHO's programme on essential dugs: background, implementation, present state and perspectives. Dan. Med. J. 1984, 31:1ff.
289. Lynch H.T., Quinn T., Severin M.J. Diethylstilbestrol, teratogenesis and carcinogenesis: medico/legal implications of its long-term sequelae, including third generation effects. Int. J. Risk Safety Med. 1990, 1(3):171-194.
290. Suing the Gun Industry: A Battle at the Crossroads and Mass Torts 2004, University of Michigan Press, Ann Arbor, MI. T.D. Lytton (Ed.).
291. MacDonald R. Prioritising neglected diseases related to poverty. BMJ 2005, 331:12.
292. Maciejewski C.S. The dilemma over foreign-language labeling of over-the-counter drugs. J. Leg. Med. 1994, 15(1):129-154.
293. Magendie F. Formulaire pour la préeparation et l'emploi de plusieurs noveaux méedicaments, comme tels que la noix vomique, la morphine, etc 1822, Mequignon-Marvis, Paris.
294. Mamdani M. Early initiatives in essential drugs policy. Drugs Policy in Developing Countries 1992, Zed Books, London. N. Kanji, A. Hardon, J.M. Harnmeijer, M. Mamdani, G. Walt (Eds.).
295. Mann J., Gostin L., Gruskin S., Brennan T., et al. Health and human rights. Health and Human Rights 1994, 1(1):6-23.
296. Mann R.D. Modern Drug Use: An Enquiry on Historical Principles 1984, MTP Press Ltd., Lancaster, Boston and The Hague.
297. Mansfield P.R. Organon, the IFMPA code and the WHO ethical criteria. MaLAM Newsletter 1992, 1. December 1992.
298. MAPS Designation of marihuana as Orphan Drug. Bull. Multidisciplinary Assoc. Psychedel. Stud. 1999, 9(3):19.
299. Marketletter FDA simplifies OTC labels. Marketletter 1994, 19 September.
300. Marks J. The Benzodiazepines-Use, Overuse, Misuse, Abuse 1978, MTP Press, Lancaster.
301. Martindale The Extra Pharmacopoeia 1977, Pharmaceutical Press, London. 27th Edition.
302. Mathiason N. Company ethics? They're not our business. Mathiason N. The Observer 2002, November 17th.
303. Matthews M. Institute for policy innovation: Senate to make world safe and profitable for drug counterfeiters and terrorists. US Newswire 2005, Statement cited in, April 19th.
304. McGarity T.O., Shapiro S.A. The trade secret status of health and safety testing information: reforming agency disclosure policies. Harvard Law Rev. 1980, 93(5):837-888.
305. Medawar C. Insult or Injury? An Enquiry into the Promotion of British Food and Drug Products in the Third World 1979, Social Audit, London.
306. Medawar C. Power and Dependence 1992, Social-Audit, London.
307. Medawar C., Hardon A. Medicines out of Control? Antidepressants and the Conspiracy of Goodwill 2004, Aksant Academic Publishers, The Netherlands.
308. Medewar C., Hardon A. Medicines out of Control? 2004, Askant Academic Publishers, The Netherlands.
309. Meltzer H.M., Aro A., Andersen N.L., Koch B., Alexander J. Risk analysis applied to food fortification. Public Health Nutrition 2003, 6(3):281-290.
310. Merrills J., Fisher J. Pharmacy Law and Practice 2001, Blackwell Science, Oxford. their edition.
311. Meyler L. Side Effects of Drugs, 1958-1960 1960, Excerpta Medical Foundation, Amsterdam, London and New York.
312. Meyler L. Schadelijke Nevenwerkingen van Geneesmiddelen. (Side Effects of Drugs) 1964, Van Gorcum & Comp, Assen.
313. Millennium United Nations Millennium Declaration, UN 2000: General Assembly Resolution 55/2 2000, (September 8th).
314. Millennium Access to Essential Medicines: Draft Final Report from Task Force 5 of the United Nations Millenium Development Goals Project: Infections Diseases and Access to Essential Medicines: Working Group on Access to Medicines 2004, UN Millenium Project, United Nations, New York.
315. Millennium Investing in Development: Millennium Project Report to the Secretary General 2005, UNDP and Earthscan, London and Sterling VA.
316. Mintzes B. Blurring the Boundaries-New Trends in Drug Promotion 1998, Health Action International, Amsterdam.
317. Mnyika K.S. Irrational drug use in Tanzania. Health Policy & Plan. 1991, 6:180-184.
318. MOH Brazil National AIDS Drug Policy 2001, 21. Ministry of Health of Brazil, Brazil at.
319. Moncrieff J., Hopker S., Thomas P. Psychiatry and the pharmaceutical industry. Psychiatric Bull. 2005, 29:84-85.
320. Moran M. Priority medicines for Europe and the world: Tuberculosis. Background Paper provided to the UN Millennium Working Group 2004, June.
321. Moses Z. The pharmaceutical industry paradox. Reuters Business Insight 2002.
322. Mossialos E., Dukes G. Affordably priced new drug for poor populations: approaches for a global solution. Int. J. Risk Safety Med. 2001, 14:1-29.
323. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. Br. Med. J. 2003, 326:1189-1192.
324. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. Br. Med. J. 2003, 326:1193-1196.
325. MRC Reports of the Salvarsan Committee (1922). II-Toxic Effects Following the Employment of Arsenobenzol Preparations 1922, Medical Research Council. His Majesty's Stationery Office, London.
326. MSF Fatal Imbalance-The Crisis in Research and Development for Drugs for Neglected Diseases 2001, Médécins sans Fontières, Geneva.
327. MSF Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVS for Developing Countries 2002, and revisions to 2005, Médécins sans Frontières, Geneva.
328. MSF Figures cited in a circular letter from the MSF-sponsored Campaign for Access to Essential Medicines, July 24th, 2002 2002, Médécins sans Frontières, Geneva.
329. MSF Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARV's for Developing Countries 2002, Médécins sans Frontières, Geneva. Second Edition.
330. MSF New Tricks to Limit Access to Affordable Medicines 2003, Access no. 9, Médécins sans Frontières, Geneva.
331. MSF Trading Away Health 2003, Access no. 9 at p. 2, Médécins sans Frontières, Geneva.
332. MSF Surmounting Challenges: Procurement of Antiretroviral Medicines in Low-and Middle-Income Countries-the experience of Médécins sans Frontières 2003, Published for the Campaign for Access to Essential Medicines, WHO and UNAIDS, Médécins sans Frontières, Geneva.
333. MSF Fatal Imbalance: Is The Bar Being Raised too High? 2003, Médécins sans Frontières, Geneva.
334. MSF Website: R&D System is Failing to Meet Health Needs in Developing Countries 2004, Briefing note as presented to the Ministerial Summit on Health Research, Mexico City, 16-20, November 2004.
335. MSF TB Care in the 21st Century 2004, Medicins sans Frontieres, Geneva.
336. MSF Access to Medicines at Risk Across the Globe. What to Watch out for in Free Trade Agreements with the United States 2004, Medicins sans Frontieres, Paris.
337. MSF R&D System is Failing to Meet Health Needs in Developing Countries 2005, Medecins sans Frontieres.
338. MSF Now That the Dust has Settled: the Consequences of the New Indian Patents Act 2005, Médécins sans Frontières, Paris.
339. MSF/AEM MSF Campaign for Access to Essential Medicines From Durban to Barcelona-Overcoming the Treatment Deficit 2002, Médécins sans Frontières, Geneva.
340. MSH MSH: Managing Drug Supply 2005, (2004 edition) Published in collaboration with the World Health Organization. Management Sciences for Health, Boston, MA.
341. MSH/WHO International Drug Price Indicator Guide: 2002 Edition 2000, and World Health Organization, Geneva, Management Sciences for Health, Boston, MA.
342. Mukherjee J. Basing treatment on rights rather than ability to pay: 335. Lancet 2004, 363:10971-11072.
343. Naik G. Glaxo Smith Kline actively pursues drug licenses. Wall Street Journal 2002, 13 February at p. B2.
344. Nairobi Nairobi Conference on Rational Use of Medicines 1985, 1987, WHO.
345. Editorial: Who says what drugs to license?. Nature 1983, 303:559. Nature.
346. NDMA See P.A.
347. Netherlands The Dutch experiments on animals act; entry into force February 5th 1997.
348. Newton P.N., White N.J., Rosendaal J.A., Green M.D. Murder by fake drugs. Br. Med. J. 2002, 324(7341):800-801.
349. Nielsen J.R. Handbook of Federal Drug Law 1986, 3. Lea & Febiger, Philadelphia, PA.
350. NIHCM NIHCM Foundation: Prescription Drugs and Intellectual Property Protection 2000, NIHCM Foundation Issue Brief: August 2000, National Institute for Health Care Management, Washington DC.
351. NIHCM National Institute for Health Care Management Research and Education Foundation: Changing Patterns of Pharmaceutical Innovation 2002, May.
352. Noah B.A., et al. Symposium: The Dietary Supplement Health and Education Act: Regulation at a Crossroads. Amer, J. Law & Med 2005, 31:141-163. 2&3.
353. DES Update. Clinical Practice of Gynecology 1992, Elsevier Science Publ. Co, New York. K.L. Noller (Ed.).
354. Norso Natural Feeling: Norso Biomagnetics 2000, 1999/2000. http://naturalfeeling.com/howitworks.html.
355. Notes taken in Court during proceedings realleged injury due to the drug B.M.; Atlanta, GA 1998.
356. NRLC National Right to Life Committee: RU 486 2005, http://www.powerweb.net/dcwrl/ru486.htm.
357. NYSRLC New York State Right to Life Commission: RU486 (2004) 2004.
358. NYTimes Lan C: Drug companies try to improve public image. New York Times 2004, 8 July.
359. OCA Organic Consumers Association (California): Debate Over Possible GE Crop Ban in California Rice Growing County 2004, Little Marais, MN.
360. OCA Organic Consumers Association: Pressure mounts for ban on GE pharm rice and other crops in US 2004, http://www.organicconsumers.org/ge/rice072604.cfm.
361. OECD Organization for European Economic Collaboration and Development: Gaps in Technology-Pharmarceuticals. (Rapporteur: Dukes M.N.G.) 1969, OECD, Paris.
362. OECD OECD Health Data 2000 2000, Organization for Economic Cooperation and Development, Paris.
363. Offerhaus L. Metamizol; een honderjarige treurnis. (Metamizol, a century of misery). Ned. Tijdsch. Geneesk. 1987, 131.
364. Offerhaus L. Metamizol; een honderjarige treurnis. (Metamizol, a century of misery). Ned. Tijdsch. Geneesk. 1987, 479.
365. Offerhaus L. Metamizol; een honderjarige treurnis. (Metamizol, a century of misery). Ned. Tijdsch. Geneesk. 1987, 1681.
366. Okie S. AMA criticized for letting drug firms pay for ethics campaign 2001, http://www.mercola.com/2001/sep/8/ama_ethics.htm.
367. A theoretical model of a National Drug Policy 2003, University of Oslo: International Master's Course in Public Health (Drug Policy Course).
368. Osmond B. A brief description of the revolving drug fund of the Khartoum comprehensive child care programme 2002, Discussion paper for the Save the Children Fund (UK).
369. Oxfam Dare to Lead: an Oxfam Briefing Paper on Glaxo Smith Kline 2001, Oxfam, Oxford.
370. Oxfam Beyond Philanthropy: The Pharmaceutical Industry, Corporate Social Responsibility and the Developing World 2002, Report from Oxfam, VSO and Save the Children, July 2002.
371. Voluntary Codes and Guidelines of the O.T.C. Medicines Industry 1984, Arts. 2-10. (The Association is now known as the Nonprescription Drug Manufacturers Association (NDMA), P.A. (Proprietary Association)P.A. (Proprietary Association), Proprietary Association, Washington, DC.
372. PAA P.A.A. Code of Practice, April 1995, Art. 3 1995.
373. PAGB Figures supplied by the Proprietary Association of Great Britain to House of Commons Select Committee 2004, 2004.
374. Palmlund I. The marketing of estrogens for menopausal and post-menopausal women. J. Psychosom. Obstet. Gynecol. 1997, 18(2):158-164.
375. Panyarachun H.E.A. Human rights and business ethics. Keynote address: International Symposium on Human Rights and Business Ethics 1998.
376. Paradise J., Sherwin B. Gene Patents 1995, Issued by the Institute on Biotechnology and the Human Future. Chicago-Kent College of Law, Chicago IL.
377. Paul J.A., Garred J. Making Corporations Accountable 2000, Global Policy Forum, New York.
378. Pavin M., Nurgozhin T., Hafner G., Yusufy F., Laing R. Prescribing practices of rural primary health care physicians in Uzbekistan. Trop. Med. Int. Health 2003, 8:182-190.
379. PCAF Buying a Law: Big Pharma's Big Money and the Bush Medicare Plan 2004, Public Campaign Action, 15 January.
380. PCGA Productivity Commission, Govermment of Australia. Paper Nr. 16: Research Report: International Pharmaceutical Price Differences. July 2001.
381. PD Anon: HK Company offers compensation to guarantee anti-SARS drug. People's Daily 2003, (Beijeng), May 13th.
382. Pear R. Drug companies increase spending on efforts to Iobby congress and governments. New York Times 2003, 1st, June, A1, 33.
383. Pécoul B. New drugs for neglected diseases: From pipeline to patients. PloS Med. 2004, 1:19-22.
384. Pécoul B., Chirac P., Trouiller P., Pinel J. Access to essential drugs in poor countries-A Lost Battle?. JAMA 1999, 281:361-367.
385. Pekkanen The American Connection 1973, 32. as cited by Medawar 2004 at, Follett Publishing, Chicago.
386. Pelman A.S., Angell M. How the drug industry distorts medicine and politics: America's other drug problem. New Republic 2002, 16 December:27-41.
387. Peninsula IANS Report: Every fourth drug sold is a fake, say medicos. The Peninsula (Qatar) 2005, 25 April.
388. Peretz Statement by Michael Peretz, executive vice-president of the International Pharmaceutical Manufactures Association (1981) as cited by Chetley 1990 (q.v.) at p. 70 1981.
389. Perez-Casas C. HIV/AIDS Medicines Pricing Report-Setting objectives: is there a political will? Update: December 2000. Campaign for Access to Essential Medicines 2000, Médecins Sans Frontières.
390. Perlman D. Drug firm seeks cures over cash. San Francisco Chronicle, August 19th 2002.
391. Pharmaceutical Research and Manufactures of America, Washington, DC. 2002.
392. Picariello Sandards for the pharmaceutical application of PAT 2005, http://www.iptonline.com/articles/piblic/ASTMlnternational.pdf.
393. PICTF Report of The Pharmaceutical Industry Competitiveness Task Force 2001, as cited by HOC 2005, PICTF, London.
394. Pinel J., Varaine F., Fermon F., et al. Des faux vaccins anti-meningocoque lors d'une epidemie de meningite au Niger. Med. Maladies Infect. 1997, 27:1-5.
395. Pjonline Second counterfe it medicine discovered in UK. Pharm. J. 2004, 273:334. http://www.pjonline.com.
396. PMAA Code of Practice, Art. 7.3 1995, Proprietary Medicines Association of Australia, North Sydney.
397. Prasad S. Insights of a paediatrician entering the pharmaceutical industry. Pharmaceut. Phys. 2003, 12(4):18-21.
398. Voluntary Codes and Guidelines of the O.T.C. Medicines Industry 1994, Proprietary Association of America, Proprietary Association, Washington, DC.
399. PSA Code of Professional Conduct 1998, Pharmaceutical Society of Australia.
400. Psaty B.M., Furberg C.D., Ray W.A., Weiss N.S. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabd omyolysis. JAMA 2004, 292:2622-2631.
401. Public Citizen Rx R&D Myths: The case against the Drug Industry's "Scare Card", Public Citizen Congress Watch 2001.
402. Public Citizen Drug Companies Deploy an Army of 675 Lobbyists to Protect Profits 2003, Public Citizen Congress Watch: The Other Drug War 2003. Consulted August 2003. http://www.citizen.org.
403. QSM Quality assurance and safety of medicines: Prequalification Project of the World Health Organization 2003, http://mednet3.who.int/prequal/about.shtml.
404. Quick J.D. Ensuring access to essential medicines in the developing countries: A framework for action. Clin. Pharm. Ther. 2003, 73:1-6.
405. RCPE RCPE Response to draft document on The Duties and Responsibilities of Pharmaceutical Physicians 2005, Royal College of Physicians of Edinburgh, Edinburgh, January 2005.
406. Revill Sleeping pill can kill, drug firm warns. Observer (London), December 5th. 2004.
407. Reye R.D.K., Moran G., Baral J. Encephalopathy and fatty degeneration of the viscera: a disease entity in childhood. Lancet 1963, 2:749.
408. RFSTE An Activit's Handbook on Intellectual Property Rights and Patents 2001, 2001, Research Foundation for Science, Technology and Ecology, New Delhi.
409. Rice T.M. Statement in the U.S. Senate: Competitive problems in the pharmaceutical industry 1999, 10:4233.
410. Richter J. Holding Corporations Accountable: Corporate Conduct, International Codes and Citizen Action 2001, Zedbooks, London and New York.
411. Richter J. Public-Private Partnerships and International Health Policy-Making. How can Pubiic interests be Safeguarded? 2004, Ministry of Foreign Affairs, Helsinki, Finland.
412. Rietveld A.H., Haaijer-Ruskamp F.M. Policy options for cost containment of pharmaceuticals. Int. J. Risk Safety. Med. 2002, 15:29-54.
413. Robin E.D. Matters of Life and Death: Risks vs. Benefits of Medical Care 1984, 81. W.H. Freeman and Company, New York.
414. Robinson J. Prescription Games 2001, Simon & Schuster, UK, London.
415. Rost P. cited in: Big Pharma given a right Rost-ing. Pharmi-Web. http://www.pharmiweb.com/pwToday/default.asp?row_id=352.
416. Rouhi A.M. Beyond Hatch-Waxman: Legislative Action Seeks to Close Loopholes in US Law that Delay Entry of Generics into the Market 2002, C & EN, Washington, DC.
417. Recent Counterfeit Alerts. Partnership for Safe Medicines. USA 2005, http://www.safemedicines.org/safety/counterfeit.html.
418. Salvarsan Reports of the Salvarsan Committee (1922): II-Toxic effects following the employment of arsenobenzol preparations 1922, His Majesty's Stationery Office, Medical Research Council, London.
419. Sanders J.C. De patienteninformatie in het kader van de produktenaansprake lijkheid. (Patient information as an aspect of product liability). Pharm. Weekbl. 1982, 117:142-144.
420. Sannerstedt R., Berglund F., Flodh H., Lundberg P., Prame B. Medication during pregnancy and breast-feeding. Int. J. Clin. Pharmacol. 1980, 18:45ff.
421. Sasisch L. (1997): Cited by Mintzes B 1998, q. v.
422. Schlosser E. Fast Food Nation - The Dark Side of the All-American Meal 2001, Houghton Mifflin, Boston and New York.
423. Schutz T.P. Returns to women's education. PHRWD Background Paper 98/001 1989, World Bank, Washington, DC.
424. Patenting Life?-An Introduction to the Issues 2005, Society, Religion and Technology Project. Church of Scotland.
425. Scrip World Pharmaceutical News (259) 1977, 9. PJB Publications, richmond.
426. Scrip's Yearbook 2000, PJB Publications, Richmond.
427. Scrip Nr. 2923, February 4th. 2004.
428. Scrip Nr. 2930, February 27th. 2004.
429. Scrip Nr. 2943/44, April 14th/16th 2004.
430. Scrip Nr. 2947, April 28th 2004.
431. Scrip Nr. 3048, April 22nd. 2005.
432. SEAM Presentations made at the SEAM/Rockefeller Foundation Symposium on Pooled Procurement 2003.
433. Shepherd M. The benzodiazepines. Prescrib. J. 1972, 12:144-147.
434. The Medicines for Human Use (Clinical Trials) Regulations 2004 2004.
435. SIF Social Investment Forum; Media Overview. 2004.
436. SIF UK Social Investment Forum: Research Reveals Increasing Burden of Corporate Responsibility Reporting 2005, London Stock Exchange, 2004/04/05.
437. Sigelman D.W. Dangerous Medicine. The American Prospect (on line), 13 (17) 2002.
438. Silverman M., Lee P.R. Pills, Profits and Politics 1974, University of California Press, Berkeley, CA.
439. Silverman M., Lee P.R., Lydecker M. Prescriptions for Death: The Drugging of the Third World 1982, University of California Press, Berkeley.
440. Silverman W.A. Human Experimentation 1985, Oxford University Press, Oxford, New York and Tokyo.
441. Simpson S. The benefits of formal training in pharmaceutical medicine - a medical director's view. Pharmaceut. Phys. 2002, 13(1):10-11.
442. Sjöström H., Nilsson R. Thalidomide and the Power of the Drug Companies 1972, Penguin Books, Harmondsworth, Middx.
443. Social Audit A suitable case for litigation?. Social Audit. London 2005.
444. Drug-induced sufferings - medical, pharmaceutical and legal aspects 1980, Excerpta Medica, Amsterdam, Oxford and Princeton. T. Soda (Ed.).
445. Spitzer E. Higher standards 2004, Paper presented to the Chautauqua Institution, July 12th.
446. SPUC Society for the Protection of Unborn Children: RU486/prostaglandin briefing 2003.
447. SRC Informatie betreffende de werkwijze van de Reclame Code Commissie. (Information on the procedures of the Netherlands Advertising Code Commission) 1993, Stichting Reclame Code, Amsterdam at p. 19; see also: Anon. (1995): Een stempel krijg je niet zomaar (You don't get a stamp of approval so easily). Zelfzorg, March, 4-6.
448. Statistics Prescriptions dispensed in the community. Statistics for 1993-2003 2004, England. http://www.publications.doh.gov.uk/prescriptionstatistics/index.htm.
449. Steinhardt R.G. Corporate Responsibility for Human Rights: International and Comparative Perspectives: The new Lex Mercatoria 2003, Institute for Public and International Law, University of Oslo.
450. Stiglitz J. The social costs of globalisation. Financial Times 2004, 13. February 25th. at.
451. Stockley I. Drug Interactions 1996, Pharmaceutical Press, London. Fourth Edition.
452. Stricker B.H.Ch. Drug-Induced Hepatic Injury 1992, 100-103. Elsevier, Amsterdam, London and New York at. Second Edition. B. Stricker (Ed.).
453. Submission Submission to the UN Millennium Commission (Working Group on Access to Medicines) by members of the Group representing the science-based industry 2004.
454. Sunartono D. Form research to action: the Gunungkidul experience. Ess. Drugs Monitor 1995, 20:21-22.
455. Swoboda The ethics of pharma-economics. An examination of the limit of corporate responsibility in the Pharmaceutical Industry. Lecture, 2 April 1999 1999, http://Web.gsia.cmu.edu/ethics/swoboda-1999.pdf.
456. Tafuri G., Creese A., Reggi V. National and international differences in the prices of branded and unbranded medicines. J. Gen. Med. 1994, 1(2):120-127.
457. Teather D., Tomlinson H. Drug firms accused of spending more on own shares than R&D. Guardian 2004, 20. October 12th at.
458. Teff H., Munro C. Thalidomide, the Legal Aftermath 1976, Saxon House, Farnborough.
459. Teixeira P.R. The Brazilian experience in universal Access to Drugs. Paper delivered to the WHO/WTO Workshop on Differential Pricing and Financing of Essential Drugs 2001.
460. Telegraph Anon. Morning-after pill advert sparks criticism. The Daily Telegraph 2002, 24 January 2002.
461. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmias suppression after myocardial infarction. N. Engl. J. Med. 1989, 321:406-412.
462. Tickell S. The Antibiotic Innovation Study: Expert Voices on a Critical Need. Report on interviews conducted for the Dag Hammarskjold Foundation 2005, Upsala, September 2005.
463. Times Anon: Drug firm "kept quiet about lethal side-effect". The Times 2004, November 23rd.
464. TPC Government of Australia (1992): Trade Practices Commission. Final Report on the self-regulation of promotion and advertising of therapeutic goods 1992, 7. ACT at, Canberra.
465. Trap B., Lessing C. ZEDAP Survey 1995 1995, Ministry of Health and Welfare, Harare.
466. Trap B., Holme H.E., Hogerzeil H.V. Prescription habits of dispensing and non-dispensing doctors in Zimbabwe. Hlth Pol Plan. 2002, 17:268-296.
467. TRIPS The TRIPS Agreement: Appendix to the Final Act of the Uruguay Round of Trade Negotiations of 1994 1994, See also.
468. UNCTAD The TRIPs Agreement and Developing Countries 1996, UNCTAD/ITE/1. UN Publications, New York and Geneva.
469. Troullier P., Olliaro P., Torreele E., Orbinski J., Laing R., Ford N. Drug development for neglected diseases: a deficient market and a public policy failure. Lancet. 2002, 359:2188-2194.
470. TRS WHO Technical Report Series 1977, No. 615.
471. Tuffs A. Bayer faces potential fine over cholesterol lowering drug. Br. Med. J. 2001, 323:415.
472. Tufts Tufts Center for the Study of Drug Development (Press Release). Tufts Center for the Study of Drug Development Pegs Cost of New Prescription Medicine at $802 Million 2001, November 30th.
473. Türmen T. Making globalisation work for better health. Development: Special issue on Responses to Globalisation-Rethinking Health and Equity 1999, 43(4):8-11.
474. TWN High Time for UN to break "Partnership" with the ICC 2001.
475. UDHR Universal Declaration of Human Rights. United Nations General Assembly, resolution 217 A (III) of 10 December 1948.
476. UN Universal Declaration of Human Rights. Art 25(1) 1948, U.N. Resolution 217 A (III), United Nations, New York.
477. UN Norms of Responsibility of Transnational Corporations and Other Business Enterprises with Regard to Human Rights 2003, UN Doc. E/CN.4/Sub.2/2003/XX, E/CN.4/Sub.2/2003/WG.2/WP.1, United Nations, New York.
478. UN, UN Economic and Social Council: (15 February 2005) Commission on Human Rights: Report of the United Nations High Commissioner on Human Rights on the responsibilities of transnational corporations and related business enterprises with regard to human rights 2005.
479. UNAIDS UNAIDS: Report on the global HIV/AIDS epidemic 2000, June 2000.
480. UNAIDS The Accelerating Access Initiative 2003, UNAIDS, Geneva.
481. UNCHR UN Commission on Human Rights. Proposed Draft Human Rights Code for Companies 2000, Geneva, 25 May 2000.
482. UNCTAD Consulted April 2005. http://globstat.unctad.org/html/lg_tncw0_data.html.
483. USS Ethics for USS Online: ISS Promotes Access to Medicine 2005, Ethics for USS, Oxford.
484. UT College of Pharmacy: Students' Handbook-Code of Ethics 1998, University of Texas, Austin, TX.
485. Van Hall E. The menopausal misnomer. J. Psychosom. Obstet. Gynecol. 1997, 18(2):59-74.
486. Vasella Drugs industry must show heart. Financial Times 2000, Cited by Pilling D., November 24th.
487. Velasquez G., Madrid Y., Quick J.D. Health Reform and Drug Financing: Selected Topics 1998, WHO, Geneva.
488. Vernick J.S., Mair J.S., Teret S.P., Sapsin J.W. Role of litigation in preventing productrelated injuries. Epidemiol. Rev. 2003, 25:90-98.
489. Von Liebig J. Über die Verbindungen, welche durch die Einwirkung des Chlors und Alkohol, Aether, ölbildenes Gas und Essiggeist entstehen. Ann Pharmacol (Heidelberg) 1832, 1:182-230.
490. Wagstaff G. Human Capital of the Poor in Vietnam 2001, as cited in Bhushan I. et al, Asian Development Bank.
491. Walsh A. (1975): Personal communication.
492. Warner S. High-priced biotech drugs: Are they worth it?. The Scientist 2004, 42-43. December 6th 2004 at.
493. Washburn L. Girl gets $4.7M for Vaccine Injuries 2002, http://www.whale.to/a/girl.html.
494. Watal J. Intellectual Property Rights in the WTO and Developing Countries 2000, Kluwer Law International.
495. Wax P.M. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann. Intern. Med. 1995, 122(6):456-461.
496. Weissbrodt D. Proposed draft human rights code of conduct for companies. Working Paper prepared for the Commission on Human Rights, Sub-Commission on the Protection and Promotion of Human Rights. 52nd Session, Item 4 of the Provisional Agenda, Working Group on the Methods and Activities of Transnational Corporations, 18 May 2000.
497. White N.J. Antimalarial drug resistance and mortality in falciparum malaria. Trop. Med. Intl. Health 1999, 4:469-470.
498. WHO Constitution of the World Health Organization 1946, WHO, Geneva.
499. WHO Ethical Criteria for Medicinal Drug Promotion 1988, WHO, Geneva.
500. WHO WHO: Ethical Criteria for Medicinal Drug Promotion 1988, paras 14-16, WHO, Geneva.
501. WHO The Role of the Pharmacist in the Health Care System. Document WHO/PHARM/DAP/90.1 1990, WHO, Geneva.
502. WHO Report of the WHO Expert Committee on National Drug Policies 1995, June. (WHO(/DAP/95.9).
503. WHO WHO: Public-Private Roles in the Pharmaceutical Sector. WHO/DAP/97.12 1997, WHO, Geneva.
504. WHO WHO/DAP: Estimating Drug Requirements-a Practical Manual 1998, WHO, Copenhagen.
505. WHO World Health Organization, Drug Action Programme: Health Reform and Drug Financing 1998, 4. Document WHO/DAP/98.3 at.
506. WHO WHO and collaborating bodies: Guidelines for Drug Donations. Revised edition, 1999. WHO/EDM/PAR/99.4 1999, WHO, Geneva.
507. WHO WHO Medicines-Strategy: Framework for Action in Essential Drugs and Medicines Policy-2000-2003 2000, See also draft of Framework for Action in Essential Drugs and Medicines Policy 2004-2007 (WHO 2003), WHO Geneva, WHO, Geneva.
508. WHO WHO/essential drugs and medicines policy: global comparative pharmaceutical expenditures with related reference information. Health Economics and Drugs. EDM Series no. 3. EDM/PAR/2000.2) 2000, 56.
509. WHO WHO/EDM 2000.1 (2000). The Essential Drugs Strategy 2000, WHO, Geneva.
510. WHO WHO: Major progress, yet huge inequities remain. WHO Policy Perspectives on Medicines 2000, 2:1. WHO, Geneva.
511. WHO WHO Policy Perspectives on Medicines 2000, 2. WHO, Geneva.
512. WHO WHO: Contry progress indicators for components of WHO Medicines Strategy 2000-2003. Policy Perspectives on Medicines 2000, 1. Table 2, WHO, Geneva.
513. WHO Resolution WHO 55.14 of the 54th World Health Assembly on Accessibility of Essential Medicines 2001.
514. WHO 25 questions and answers on health and human rights. Health and Human Rights Publication Series 2002, 1:10. WHO, Geneva.
515. WHO WHO: Global Strategy for Traditional and Complementary Alternative Medicine 2002-2005 2002, WHO, Geneva.
516. WHO Promoting rational use of medicines: core components. WHO Policy Perspectives on Medicines 2002, 5. WHO, Geneva.
517. WHO WHO: How to Develop and Implement a National Drug Policy 2002, WHO, Geneva. Second Edition.
518. WHO WHO: Core Indicators for Monitoring National Drug Policies 2002, WHO, Geneva.
519. WHO WHO: Access to essential medicines is fundamental to human rights. Policy Perspectives on Medicines 2002, 4. WHO, Geneva.
520. WHO Effective medicines regulation: Ensuring safety, efficacy and quality. WHO Policy Perspectives on Medicines, Nr. 7 2003, WHO, Geneva.
521. WHO Resolution WHO 56.27 of the 56th World Health Assembly on Intellectual Property Rights, Innovation and Public Health 2003.
522. WHO World Health Report 2003: Shaping the Future 2003, World Health Organization, Geneva.
523. WHO Substandard and Counterfeit Medicines 2003, WHO Fact sheet no. 275 November 2003, WHO, Geneva.
524. WHO WHO Model List of Essential Medicines 2003, WHO, Geneva.
525. WHO The quality of antimalarials-a study in selected African countries 2003, WHO, Geneva. C. Maponga, C. Ondari (Eds.).
526. WHO How to develop and implement a national drug policy. WHO Policy Perspectives on Medicines, 6 2003, WHO, Geneva.
527. WHO WHO Model Formulary 2003, WHO, Geneva, ISBN 92 4 254559 3.
528. WHO WHO Fact Sheet no. 274 (3 by 5 programme for HIV/AIDS) September 2003 2003, WHO, Geneva.
529. WHO WHO Medicines Strategy: Countries at the Core 2004-2007. WHO/EDM/2004.5 2004, WHO, Geneva.
530. WHO The World Medicines Situation 2004, World Health Organization, Geneva.
531. WHO WHO: Priority Medicines for Europe and the World. WHO/EDM/PAR/2004 2004, WHO, Geneva.
532. WHO/Bhutan WHO: Bhutan Essential Drugs Programme: A Case History. WHO/EDM/DAP/2000.2 2002, WHO, Geneva.
533. WHO/EURO Guidelines for the Assessment of Medicinal Products for Use in Self-Medication 1986, WHO Regional Office for Europe, Copenhagen.
534. WHO/EURO Clinical Consensus Document: The Clinical Investigation of Drugs Used in the Treatment of Rheumatic Diseases 1988, WHO, Regional Office for Europe, Copenhagen.
535. WHO/EURO Clinical Pharmacological Evaluation in Drug Control 1993, EUR/ICP/DSE 173, World Health Organization, Regional Office for Europe, Copenhagen.
536. WHO/EURO WHO Regional Office for Europe: Drug Utilization Studies: Methods and Uses. WHO Regional Publications: European Series No. 45 1993, WHO, Regional Office for Europe, Copenhagen. M.N.G. Dukes (Ed.).
537. WHO/EURO World Health Organization. Clinical Pharmacological Evaluation in Drug Control. EUR/ICP/DSE 173 1993, WHO, Copenhagen.
538. WHO/EURO Drugs and Money 2003, and IOS Press, Amsterdam, WHO Regional Office for Europe, Copenhagen. Seventh Edition. M.N.G. Dukes, F.M. Haaijer-Ruskamp, C.P. de Joncheere, A.H. Rietveld (Eds.).
539. WHO/HAI Medicine Prices-a New Approach to Measurement 2003, WHO and Health Action International, Geneva. 2003 Edition.
540. WHO/IFPMA Improving Access to Essential Drugs Through Innovative Partherships 2000, WHO, Geneva.
541. Willis S.H., Ruger J.R. Pharmacoepidemiology: a view from the US courtroom. Pharmacoepidemiology 1994, Wiley, Chichester, New York and Baltimore. Second Edition. B. Strom (Ed.).
542. Wilson R.A. Feminine Forever 1966, M. Evans, New York.
543. Wilson R.A., Wilson T. The fate of non-treated postmenopausal women: a plea for the maintenance of adequate estrogen from puberty to the grave. J. Am. Geriatr. Soc. 1963, 11:347-361.
544. WMA Declaration of Helsinki. 1964, 1975, 1983, 1989, 1996 and ongoing 1996, World Medical Association, Helsinki.
545. WOG Wet op de Geneesmiddelenvoorziening 1958, (Netherlands Medicines Act).
546. Wood A.J.J., Zhou H.H. Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet. 1991, 20:350-373.
547. World Bank Guidelines for the Development of Drug Policy in Developing Countries 1993, (Stencil).
548. World Bank World development Report 1993: Investing in Health 1993, World Bank, Washington DC.
549. World Bank Broun D. and Dukes G. National Drug Policies and Use of Resources: A Briefing Paper 1993, World Bank, Washington, DC.
550. WSMI Prescription to non-prescription switch. World Self-Medication Industry 2005.
551. WTO WTO Council for Trade-Related Aspects of Intellectual Property Rights, Special Discussion on Intellectual Property and Access to Medicines, 4, WTO Doc No IP/C/M/31 (Restricted) (July 10, 2001) 2001.
552. Xavier N.B. Patents for Future 2001, Vakils, Feffer and Simons, Mumbai.
553. Yamey G. Public sector must develop drugs for neglected diseases. Br. Med. J. 2002, 324:698.
554. Yellowcard MHRA: Essential Information about Drug Analysis Prints 2005, Medicines and Healthcare Products Regulatory Agency, London.
555. Yemen Government of Yemen: Statistical Report of the Supreme Board of Drugs and edical Appliances. Sanaa 1996.
556. Yuan L. Towards systematic analysis and policy recommendations for ATEM 2004, Presentation to U.N. Millennium Task Force Nr 5.
557. Zaveri N.B. Patents for future for mankind, future for inventor & owner, future for science and technology 2001, Vakils, Feffer & Simons, Mumbai.